Backgroundlo increase the coverage of influenza vaccina-
Introduction
In The Netherlands, as well as in other Western countries, mortality owing to the complications of influenza is relatively high. For The Netherlands, estimates range from 2000 deaths a year for the age-groups of 60 years and over to 4000 a year for all age-groups. Also, many people have to be admitted to hospital because of complications caused by influenza, such as pneumonia. In particular, patients with cardiovascular diseases, lung and bronchia diseases or diabetes mellitus are at risk. Vaccination of high-risk patients against influenza diminishes the chance of complications or death. 2 In The Netherlands, vaccination caused a 50 per cent reduction in the incidence of influenza amongst older persons. 3 The level of protection by the vaccine depends on age. The protection in young adults is about 70-90 per cent; in older persons it is much less. It is also known that vaccination against influenza reduces the costs of health care. 4 " 7 In The Netherlands, about 12 per cent of the population living independently belongs to the population at risk, as mentioned in earlier studies. ' The vaccination coverage in The Netherlands is relatively low, compared with countries such as France, the United Kingdom and Canada. 9 ' 10 In 1991, about 28 per cent of the population at risk was vaccinated, as can be derived from figures of the National Health Interview Survey (NHIS). In 1992, the coverage was almost 40 per cent, and in 1993, 42 percent."
Results from some small experiments in The Netherlands show that it is possible to increase the coverage in a small population. Personal invitation by the general practitioner (GP) seems to be an important factor in this increase.
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To check if it is possible to increase the vaccination coverage in a large population, TNO (the Netherlands organization for applied scientific research) Prevention and Health (TNO-PG, an independent research institute) carried out an experiment (total cost about 700000 Dutch guilders) in a region in the south of The Netherlands (the city of Tilburg and surroundings). This urbanized region can be considered as more or less representative of the densely populated Netherlands.
Before elaborating on the methods and results, we first have to explain something about the Dutch health care system and prevention, because the experiment relies on the existing institutions and procedures in the health care system.
Dutch health care system
In the Dutch health care system, most prevention programmes are carried out by special public health services. For instance, screening for breast cancer (mostly) takes place in special bureaux. This specialization is possible because most prevention programmes are aimed at specific age and/or sex groups (children, women in specific age-groups, etc.) and selection is therefore relatively easy. However, for vaccination against influenza, the selection of risk groups is based on medical criteria rather than age. Almost every person in The Netherlands has a GP who has medical records of all his or her patients. For this reason, GPs play a key role in influenza vaccination. Almost every person also has their own pharmacist, who keeps computerized records of the medicines used by the patients. The combination of these two databases makes it easier to select and invite patients at risk for influenza vaccination. For many GPs the selection of patients at risk is a difficult task, because they do not have a computerized medical database of their patients and they cannot easily select patients at risk by hand. Therefore, it is useful to employ the information that pharmacists have about medicines used by the patients. Use of certain medicines can be considered as an indication of one or more risk groups. For instance, use of insulin (as can be found in the pharmacists' database) refers to diabetes mellitus. In other cases, however, the relationship between medicine and disease is ambiguous. The pharmacist can select patients at risk based on the medicines used, but the GP has to decide whether or not the patients selected by the pharmacist really are at risk. On the other hand, the GP can also add to the list patients who do not use medicines but who are at risk, for instance, diabetes patients with a special diet only.
Not only the selection, but also the making of the invitations can create a problem for the GPs, especially when they do not have a computerized patient database. Therefore, the TNO-PG experiment was mainly directed towards these logistic problems, giving assistance with the selection and invitation of the patients.
Finally, some remarks about the reimbursement system for influenza vaccination have to be made: for most patients at risk the insurance company (be it National Health or private) pays for the vaccine and the vaccination. A minority of the patients with private insurance have to pay for the vaccination itself. This depends on the conditions of the insurance company.
Methods
The experiment was conducted in the second half of 1993 in a region with about 262000 inhabitants. All 110 GPs and 38 pharmacists were invited to participate. For various reasons, only 56 GPs (in 42 practices) and 27 pharmacists were involved. For GPs the main reasons for not participating were that they carried out their own activities for vaccination that were not compatible with the activities in the experiment (e.g. they placed announcements in local newspapers), and the fact that a few pharmacists that they worked with could not co-operate. For pharmacists the main reasons for not participating were the fact that they could not deliver the data on diskette (a prerequisite for participation), and the fact that some GPs they worked with did not participate. In total, the 42 practices cover about 133 000 patients (that is, over 50 per cent of the population of the region). Neither GPs nor pharmacists were offered any incentives to participate in the research project.
The participating GPs did not differ from the nonparticipants, in terms of sex and age, the number of patients in the practice and the number of patients vaccinated against influenza in 1992.
The following activities were conducted: (1) Pharmacists selected patients on the basis of use of medicines. For this they used a list of medicines compiled by the Royal Dutch Association for the Advancement of Pharmacy. This list contains all medicines whose use is possibly related to one of the underlying diseases mentioned in the Introduction.
(2) TNO-PG collected the data, sorted it by GP and mailed it to the GPs concerned. Data included name, address, sex, age and medication used by the patients and the name of the GP.
(3) GPs judged the patients on the list. They removed patients who were not at risk (false positives) and added patients at risk who were not initially on the list (false negatives). Of the patients added, the GPs also provided information about the risk group(s) to which the patient concerned belonged.
(4) TNO-PG invited the patients on behalf of the GPs.
(5) Finally, the GPs (or their assistants) vaccinated the patients who responded to the invitation.
Analyses were conducted on data provided by pharmacists and GPs. Most of these data were collected in the process of normal care-delivery and registration, and not particularly for research. The vaccination coverage was compared with the results obtained from the NHIS in The Netherlands in the same year. Table 1 gives a summary of the results. Almost 20 000 patients were selected by the pharmacists because of the medicines used. Of these, about 7600 (38 per cent) were removed by the GPs, because in their view they were not at risk. Therefore, from the patients selected by the Table 2 gives the results for different risk groups. Information about medication does not automatically provide information about the risk group to which the patients belong. In some cases, a medicine refers to a particular disease (for instance, insulin and diabetes), in other cases to more than one disease (beta-blockers). The situation becomes even more complicated when a patient has medication for more than one disease. Therefore, in Table 2 , patients who have only one type of medication or belong to only one risk group are presented under 'single indication'. The heading 'other medical indication' refers mainly to patients who had an influenza vaccination in the year before the experiment, without any other known medical indication. Patients with more than one type of medication are presented under the heading 'multiple indication'. The heading 'non-medical indication' refers to patients who have been added to the list because of other factors, for instance age. The heading 'indication unknown' refers to the group for which no information was available. In some cases the GPs judged patients to belong to more than one risk group, so these patients are counted more than once. Therefore, the total number of vaccinated patients in Table 2 is higher than in Table 1 .
Results
From Table 2 , it can be seen that vaccination is highest in the groups 'other medical indication' and 'non-medical indication'. The high coverage in the group 'other medical indication' might be due to the fact that this group contains persons who have had vaccinations before and who therefore might be used to being vaccinated against influenza.
The lowest percentage of vaccination is found in the group 'lung and bronchia diseases'. This might be due to the fact that these patients do not judge themselves as being at risk and therefore see no need for vaccination.
Vaccination coverage is also high in the group of patients with a multiple indication. Although a multiple indication does not automatically implicate a multiple risk group, it can be assumed that most patients do belong to more than one risk group. For this type of patient, vaccination is very important, because the presence of more underlying diseases leads to a greater chance of suffering from complications. Table 3 shows the increase in the vaccination coverage between 1992 and 1993. This increase is calculated in two different ways. The first calculation is based on the sales figures of the pharmacists over the years 1992 and 1993. These figures are available for both those GPs who participated in the experiment and those who did not. The second calculation is based on the figures produced by the GPs themselves. Over the year 1992 they estimated the number of vaccinated patients. Over the year 1993 we have the exact number of patients vaccinated. The information on The Netherlands in total is based on the Health Interview Surveys.
In 1993, compared with 1992, the pharmacists sold 56 per cent more influenza vaccines to patients of participating GPs. The increase in sales to patients of non-participating GPs was only 18 per cent. The participating GPs themselves report an overall increase of 51 per cent. The small difference between the figures of the pharmacists and the GPs might be due to the fact that the GPs had to estimate the number of patients vaccinated in 1992 and that the figures from the pharmacists include patients who are not at risk, not invited, but vaccinated at their own request. In The Netherlands as a total, the increase was about 8 per cent." In 1993 about 42 per cent of the population at risk was vaccinated, which is much below the percentage of 75-5 per cent that was found in the experimental region. That is why the main conclusion from this experiment is that the vaccination coverage has greatly increased, thanks to the interventions undertaken.
Discussion
This experiment was set up to see what is feasible in the vaccination against influenza and to learn what is possible in a large-scale implementation. It is not clear what the limit of the vaccination coverage will be, but we are convinced that the 76 per cent of the patients at risk vaccinated in this experiment can be increased further, because some participating GPs have added only a few patients. The coverage can be improved by better opportunities for the selection of patients, for instance by means of the current computerization of medical data in the practice.
In our study, we compared the coverage in the region with the coverage as reported from the NHIS. Some remarks have to be made on this comparison. The results from the NHIS are based on reports of the respondents themselves. It is known that these reports sometimes differ from the diagnosis made by professionals. 17 These differences are most prominently present in lung and bronchia diseases. However, the total percentage of patients at risk found in the NHIS equals that found in our study.
The main conclusion of our study is that it is possible to increase the vaccination coverage in a large population by a programmatic approach of vaccination against influenza. In The Netherlands as a whole, this coverage is about 42 per cent, which is much lower than the 76 per cent reached in the experimental region. The way the logistic problems are handled in this experiment leads to an increase in the vaccination coverage, but it is rather time consuming and also complex. We think that implementation on a national scale requires that the GPs themselves (or their assistants) carry out the tasks of selecting and in particular inviting the patients at risk, for we think that the personal, written invitation is essential for a high response.
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15 However, if we rely only on the GPs for this upscaling, it is not inconceivable that only the enthusiastic GPs will be able to handle the procedure of selection and invitation on their own. For many practitioners this will remain a problem. From a public health viewpoint, this is unsatisfactory because a part of the population at risk is not given the opportunity to be vaccinated. Upscaling this experiment will therefore still require logistic support in one form or another. When the computerization of the medical databases within the practices continues, selection and invitation will become easier, but this requires another kind of support: teaching the proper use of computerized medical databases.
